Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.QRxPharma has completed two Phase I studies in healthy volunteers for MoxDuo CR, a controlled-release Dual-Opioid utilizing a 3:2 ratio of morphine and oxycodone.
Subscribe to our email newsletter
The trials evaluated blood levels of MoxDuo CR’s components to OxyContin and MS Contin and demonstrated MoxDuo CR’s superior results, with sustained blood levels for up to 24 hours.
Further studies indicated MoxDuo CR’s increased resistance to tampering, the company said.
The MoxDuo CR tablets used in these clinical tests included QRxPharma’s proprietary Abuse Deterrence Formulation (ADF) technology.
The company expects to launch MoxDuo CR into the US chronic pain market in 2015.
QRxPharma managing director and chief executive officer John Holaday said the successful completion of the trials confirm the advantages of the formulation and enables QRxPharma to initiate Phase II Proof-of-Concept clinical studies mid-year 2012.
"These data suggest MoxDuo CR may be positioned as a once or twice per day formulation for treating chronic pain, with the potential advantage of significantly reduced side effects as witnessed with immediate release MoxDuo," Holaday added.